Table 1 Clinical pathological characteristics of DLBCL cases identified in the training and validating datasets
Clinical features | Training cohort | Validating cohorts | ||||
|---|---|---|---|---|---|---|
GSE181063 (n = 644) | NCICCR (n = 234) | GSE10846 RCHOP(n = 233) | GSE10846 CHOP (n = 181) | GSE11318 (n = 163) | ||
Tissue | unknown | lymph node | lymph node | lymph node | lymph node | |
Firstline regimen | RCHOP | RCHOP or CHOP | RCHOP | CHOP | CHOP | |
Event | Â | Â | Â | Â | Â | |
0 | 354(54.97%) | 136(58.12%) | 173(74.25%) | 76(41.99%) | 67(41.10%) | |
1 | 290(45.03%) | 98(41.88%) | 60(25.75%) | 105(58.01%) | 96(58.90%) | |
Gender | Â | Â | Â | Â | Â | |
Female | 326(50.62%) | 95(40.60%) | 99(42.49%) | 73(40.33%) | 73(44.79%) | |
Male | 318(49.38%) | 139(59.40%) | 134(57.51%) | 90(49.72%) | 90(55.21%) | |
unknown | 0 | 0 | 0 | 18(9.94%) | 0 | |
Age | Â | Â | Â | Â | Â | |
≤ 60 | 190(29.50%) | 116(49.57%) | 113(48.50%) | 75(41.44%) | 69(42.33%) | |
> 60 | 454(70.50%) | 118(50.43%) | 120(51.50%) | 106(58.56%) | 94(57.67%) | |
ECOG, PS | Â | Â | Â | Â | Â | |
< 2 | 473(73.45%) | 163(69.66%) | 158(67.81%) | 138(76.24%) | 122(74.85%) | |
≥ 2 | 121(18.79%) | 49(20.94%) | 52(22.32%) | 41(22.65%) | 39(23.93%) | |
unknown | 50(7.76%) | 22(9.40%) | 23(9.87%) | 2(1.10%) | 2(1.23%) | |
Ann Arbor stage | Â | Â | Â | Â | Â | |
I + II | 223(34.63%) | 110(47.01%) | 105(45.06%) | 83(45.86%) | 75(46.01%) | |
III + IV | 351(54.50%) | 121(51.71%) | 121(51.93%) | 97(53.59%) | 87(53.37%) | |
unknown | 70(10.87%) | 3(1.28%) | 7(3.00%) | 1(0.55%) | 1(0.61%) | |
LDH | Â | Â | Â | Â | Â | |
>UNL | 327(50.78%) | 105(44.87%) | 93(39.91%) | 85(46.96%) | 76(46.63%) | |
≤UNL | 193(29.97%) | 97(41.45%) | 99(42.49%) | 74(40.88%) | 68(41.72%) | |
unknown | 124(19.25%) | 32(13.68%) | 41(17.60%) | 22(12.15%) | 19(11.66%) | |
Cell of origin | Â | Â | Â | Â | Â | |
GCB type | 306(47.52%) | 110(47.01%) | 107(45.92%) | 76(41.99%) | 66(40.49%) | |
ABC type | 179(27.80%) | 82(35.04%) | 93(39.91%) | 74(40.88%) | 70(42.94%) | |
MHG type | 45(6.99%) | 0 | 0 | 0 | 0 | |
UNC type | 114(17.70%) | 42(17.95%) | 33(14.16%) | 31(17.13%) | 27(16.56%) | |
B symptoms | Â | Â | Â | Â | Â | |
Yes | 247(38.35%) | unknown | unknown | unknown | unknown | |
No | 397(61.65%) | unknown | unknown | unknown | unknown | |
IPI score | Â | Â | Â | Â | ||
0–2 |  | 277(43.01%) | 126(53.85%) | unknown | unknown | unknown |
3–5 |  | 208(32.30%) | 67(28.63%) | unknown | unknown | unknown |
unknown | Â | 159(24.69%) | 41(17.52%) | unknown | unknown | unknown |
Extranodal involvement | Â | Â | Â | Â | Â | |
Yes | Â | 254(39.44%) | 111(47.44%) | 116(49.79%) | 29(16.02%) | 28(17.18%) |
No | Â | 305(47.36%) | 109(46.58%) | 87(37.34%) | 151(83.43%) | 134(82.21%) |
unknown | Â | 85(13.20%) | 14(5.98%) | 30(12.88%) | 1(0.55%) | 1(0.61%) |